Antibiotic Mechanisms

Definition

• Antibiotic mechanism of action refers to the specific bacterial macromolecule an agent attacks — cell wall (peptidoglycan) assembly, the 30S or 50S ribosome, DNA gyrase/topoisomerase IV, RNA polymerase, or folate synthesis. Selectivity comes from targeting structures absent or structurally divergent in human cells (peptidoglycan, 70S ribosome, bacterial dihydrofolate reductase).
• Bactericidal vs bacteriostatic distinction drives therapy in sites where host immunity cannot finish the job: endocarditis, meningitis, osteomyelitis, and neutropenia favor bactericidal, ideally cell-wall–active, agents.

Why it matters clinically

• Mechanism predicts spectrum, tissue penetration, synergy, and — most importantly for exams — the resistance mechanism that will defeat the drug (β-lactamase, altered PBP, ribosomal methylation, efflux, porin loss).
• Mechanism also predicts toxicity: agents that concentrate in the renal cortex and cochlea (aminoglycosides, vancomycin) demand level monitoring; agents that inhibit CYP enzymes (macrolides) cause interaction-driven harm.

Epidemiology worth recalling

• The CDC 2019 Antibiotic Resistance Threats Report attributed roughly 2.8 million antimicrobial-resistant infections and more than 35,000 deaths annually in the United States.
• CDC urgent threats include carbapenem-resistant Enterobacterales, carbapenem-resistant Acinetobacter, drug-resistant Neisseria gonorrhoeae, Clostridioides difficile, and Candida auris; MRSA and drug-resistant Streptococcus pneumoniae are classed as serious threats.
• About one in ten U.S. patients carries a reported penicillin allergy, yet the large majority tolerate penicillin on formal testing — a labeling problem that pushes patients toward broader, more toxic, and less effective alternatives (CDC and AAAAI both endorse allergy delabeling).
• Antibiotic exposure itself is the dominant modifiable risk factor for C. difficile infection, with clindamycin, fluoroquinolones, and broad-spectrum β-lactams most implicated.

β-lactams (penicillins, cephalosporins, carbapenems, monobactams)

• Target: acylate the active site of penicillin-binding proteins (transpeptidases), blocking peptidoglycan cross-linking; unopposed autolysins then degrade the wall → osmotic lysis. Killing requires actively dividing bacteria. Separately, organisms with no peptidoglycan (Mycoplasma, Ureaplasma) are intrinsically resistant to all cell-wall–active agents.
• PK that changes decisions: killing is time-dependent (%time above MIC), so frequent dosing, prolonged infusions, or long-half-life agents (ceftriaxone, once daily) are used rather than large intermittent boluses. Most are renally cleared and need renal dose adjustment; nafcillin/oxacillin and ceftriaxone are hepatically/biliary eliminated and do not. Penetration into CSF is poor unless meninges are inflamed. Probenecid blocks tubular secretion and raises penicillin levels.
• Resistance: β-lactamases (including ESBLs and carbapenemases), altered PBP target (mecA → PBP2a in MRSA; mosaic PBPs in penicillin-resistant pneumococcus), and porin loss/efflux in Gram-negatives.

Aminoglycosides (gentamicin, tobramycin, amikacin)

• Target: irreversible binding to the 30S subunit, causing misreading of mRNA and defective initiation → bactericidal despite being protein-synthesis inhibitors.
• Uptake is oxygen-dependent, so anaerobes and abscess/acidic environments are refractory; polycationic structure means no oral absorption, negligible CSF entry, and pure renal excretion.
• PK: concentration-dependent killing with a long post-antibiotic effect justifies extended-interval (once-daily) dosing, which maximizes peak/MIC while minimizing tubular and cochlear accumulation. Synergy with cell-wall–active agents reflects easier drug entry through a damaged wall.
• Resistance: aminoglycoside-modifying enzymes (acetyl-, phospho-, adenylyltransferases) and ribosomal methylation.

Vancomycin

• Target: binds the D-Ala-D-Ala terminus of the pentapeptide precursor, sterically blocking transglycosylation and transpeptidation — a substrate-binding, not enzyme-binding, mechanism, so β-lactamases are irrelevant.
• Large, polar glycopeptide: not absorbed orally (oral form treats luminal C. difficile only), IV for systemic infection, and renally cleared; serious infections are dosed to a 24-hour AUC as described in the Quick Facts and Clinical Use sections.
• Resistance: vanA/vanB substitution of terminal D-Ala with D-Lac, collapsing binding affinity (VRE).

β-lactams — the workhorses

• Penicillin G remains first-line and irreplaceable for syphilis; per the CDC STI Treatment Guidelines, early syphilis is treated with benzathine penicillin G 2.4 million units IM as a single dose, and pregnant patients with reported allergy require desensitization rather than substitution.
• Penicillin or amoxicillin is first-line for group A streptococcal pharyngitis (IDSA), with no documented resistance; amoxicillin is also first-line for acute otitis media (AAP) and, in high dose, for penicillin-nonsusceptible pneumococcus.
• Antistaphylococcal β-lactams (nafcillin, oxacillin, cefazolin) are preferred over vancomycin for MSSA bacteremia and endocarditis — better outcomes than glycopeptides.
• Ceftriaxone is first-line for gonorrhea as a single 500 mg IM dose (CDC 2021 STI guidelines).
• Empiric bacterial meningitis is age-stratified (IDSA):
• Adults over 50 or immunocompromised: ceftriaxone + vancomycin + ampicillin, the ampicillin specifically for Listeria.
• Neonates: ampicillin plus cefotaxime, or ampicillin plus an aminoglycoside (gentamicin) — ceftriaxone is avoided in neonates because it displaces bilirubin from albumin (kernicterus risk).
• Carbapenems are preferred for serious ESBL-producing Enterobacterales infection per IDSA guidance on antimicrobial-resistant Gram-negatives; aztreonam covers Gram-negatives in true severe β-lactam allergy.

Vancomycin

• IV vancomycin is first-line for MRSA bacteremia, endocarditis, and osteomyelitis, and is part of empiric therapy in severe sepsis and in hospital-acquired/ventilator-associated pneumonia when MRSA risk factors are present (IDSA/ATS HAP-VAP guideline); AUC-guided dosing applies to serious infection.
• Oral vancomycin or fidaxomicin treats C. difficile infection; the IDSA/SHEA update favors fidaxomicin for initial and recurrent episodes, with oral vancomycin an acceptable alternative. Metronidazole is no longer preferred.

Aminoglycosides

• Used for serious aerobic Gram-negative infections, often with a β-lactam, and for synergy in enterococcal or staphylococcal endocarditis; extended-interval dosing is standard, with traditional divided dosing retained for synergy indications.
• Generally avoided in pregnancy (fetal cranial nerve VIII toxicity) and reserved for infections with no safer alternative.
• Streptomycin/amikacin have niche roles in mycobacterial disease; oral/inhaled aminoglycosides exploit poor absorption for gut decontamination and cystic fibrosis airway therapy.

β-lactams

• IgE-mediated anaphylaxis: urticaria, bronchospasm, hypotension within minutes — treat with epinephrine 0.3 mg IM. A benign delayed maculopapular rash is far more common and does not preclude future β-lactam use, but severe delayed reactions (SJS/TEN, DRESS, interstitial nephritis) are absolute contraindications to rechallenge.
• Amoxicillin/ampicillin rash in acute EBV infection: non-allergic, T-cell mediated, does not predict penicillin allergy.
• Acute interstitial nephritis is a class-wide β-lactam effect (and occurs with many other drug classes, notably NSAIDs, sulfonamides, and PPIs), historically associated with methicillin/nafcillin — fever, rash, eosinophilia, WBC casts; withdraw the drug.
• Coombs-positive hemolytic anemia, neutropenia, and drug fever with prolonged high-dose therapy.
• Ceftriaxone: biliary sludging and displacement of bilirubin from albumin → avoid in neonates (use cefotaxime). Cephalosporins with an NMTT side chain (cefotetan) cause hypoprothrombinemia and disulfiram-like reactions.
• Imipenem lowers seizure threshold, especially with renal impairment or CNS lesions; meropenem is preferred when seizure risk matters.
• All β-lactams disrupt colonic flora → C. difficile colitis.

Aminoglycosides

• Ototoxicity: cumulative destruction of cochlear and vestibular hair cells; often irreversible, and additive with loop diuretics and vancomycin. Baseline and serial audiometry for prolonged courses.
• Nephrotoxicity: proximal tubular uptake → non-oliguric acute tubular necrosis, usually reversible; monitor creatinine and drug levels, avoid volume depletion, NSAIDs, contrast, and amphotericin.
• Neuromuscular blockade by presynaptic calcium antagonism — avoid in myasthenia gravis and use caution with anesthetic paralytics.
• Generally avoided in pregnancy because of fetal cranial nerve VIII toxicity, consistent with the Clinical Use section.

Vancomycin

• Vancomycin flushing syndrome (formerly "red man syndrome"): direct, non-IgE mast cell histamine release from rapid infusion → upper-body flushing and pruritus. Slow the infusion and pretreat with an antihistamine; this is not an allergy.
• Nephrotoxicity, amplified in combination with piperacillin-tazobactam; the AUC-guided dosing strategy referenced earlier exists specifically to reduce this. Also DRESS, neutropenia, and thrombocytopenia.
• No specific antidote exists for aminoglycoside or vancomycin toxicity — management is drug withdrawal, supportive care, and renal replacement in extreme overdose.

• ***mecA* → PBP2a is the MRSA mechanism: an altered target with low β-lactam affinity, so β-lactamase inhibitors do not** restore activity. The distractor is "add clavulanate" — the correct answer is a different class (vancomycin) or a PBP2a-active cephalosporin (ceftaroline).
• ***vanA* → D-Ala-D-Lac substitution** is the VRE mechanism. Recognize it as loss of substrate binding, not enzymatic drug destruction.
• Aminoglycoside failure in an abscess is the classic vignette: uptake is oxygen- and pH-dependent, so drainage — not a higher dose — is the single best next step.
• MSSA bacteremia is a β-lactam disease: switch from empiric vancomycin to nafcillin, oxacillin, or cefazolin once susceptibility returns. Staying on vancomycin is the tested error.
• Oral vancomycin is not systemic therapy — no absorption means it treats only luminal C. difficile. Conversely, **IV vancomycin does not treat *C. difficile***.
• Vancomycin flushing syndrome is infusion-rate–dependent histamine release, not IgE allergy; slow the infusion rather than abandoning the drug. Contrast this with true anaphylaxis.
• Aztreonam is the β-lactam that is safe in severe penicillin allergy because it is monocyclic and not cross-reactive with penicillins — but it shares an R1 side chain with ceftazidime, the one cross-reaction examiners like.
• No peptidoglycan, no cell-wall drug: Mycoplasma is intrinsically resistant to all β-lactams and vancomycin — reach for a macrolide, tetracycline, or fluoroquinolone.
• Ceftriaxone is not a neonatal drug: bilirubin displacement means empiric neonatal meningitis is ampicillin plus cefotaxime (or gentamicin), while the over-50/immunocompromised adult gets ceftriaxone + vancomycin + ampicillin.
• Vancomycin is dosed to a 24-hour AUC (AUC/MIC 400–600) per the 2020 IDSA/ASHP consensus; the distractor is the retired trough-only goal of 15–20 mcg/mL.

• Cell wall inhibitors (β-lactams, vancomycin) are bactericidal; most effective during active growth
• Protein synthesis inhibitors (aminoglycosides, tetracyclines, macrolides, chloramphenicol) are typically bacteriostatic (except aminoglycosides, which are bactericidal)
• Fluoroquinolones inhibit DNA gyrase/topoisomerase IV; bactericidal
• Sulfonamides/trimethoprim inhibit folate metabolism (sequential blockade); bacteriostatic
• Rifampin inhibits bacterial RNA polymerase; bactericidal

• Penicillin allergy → cephalosporins are usually safe (true cross-reactivity is about 1%, driven by shared R1 side chains rather than the beta-lactam ring) or carbapenems
• Gram-negative sepsis → aminoglycosides or fluoroquinolones
• Atypical pneumonia (Mycoplasma, Chlamydia) → macrolides or tetracyclines
• Vancomycin monitoring: AUC-guided dosing (AUC/MIC 400-600) for serious MRSA infection; trough-only goals of 15-20 mcg/mL are no longer recommended (2020 IDSA/ASHP consensus)

Mnemonic—Gram-negative coverage

• 3rd/4th gen cephalosporins, fluoroquinolones, aminoglycosides, carbapenems

Mnemonic—Atypical coverage (CALm)

• Chlamydia, Amycoplasma, Legionella → macrolides, fluoroquinolones, tetracyclines

1. 1.Aminoglycosides require aerobic gram-negative bacteria and active cell wall inhibition for synergy—they are useless in anaerobes and poorly effective alone in monotherapy (except as empiric coverage)
2. 2.Cephalosporin allergy is NOT absolute in penicillin-allergic patients (only 1–3% true cross-reactivity with 3rd/4th generation; higher with 1st generation). Always assess type of penicillin reaction before excluding.
3. 3.Vancomycin is NOT first-line for MRSA UTI or uncomplicated infections—reserve for severe infections, endocarditis, or CNS penetration needed; fluoroquinolones/TMP-SMX preferred for uncomplicated UTI

Selection depends on organism and site

• Bacterial pneumonia (CAP): Amoxicillin/amoxicillin-clavulanate (Gram+/−); add macrolide or fluoroquinolone for atypicals
• Skin/soft tissue: Cephalexin or amoxic